RxDoctor Payments Data

Svetlana Schwartz, APRN

Psychiatric/Mental Health · Davie, FLNPI 1639395528

Payments from drug & device makers

$1,809in general payments, 2019–2025

Across 37 payments — averaging $48.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Johnson & Johnson$326
  • Teva Pharmaceuticals USA, Inc.$119
  • AbbVie$108
  • Otsuka America Pharmaceutical, Inc.$94
  • Neurocrine Biosciences, Inc.$30
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$1,809100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,809 in reported general payments places this provider in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$6,616
Medicare patients
33
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate46$103,696
Abilify MaintenaAripiprazole14$38,746
LybalviOlanzapine/Samidorphan Malate15$23,341
Aripiprazole35$12,670
TrintellixVortioxetine Hydrobromide12$5,783
Quetiapine Fumarate143$4,983
Lurasidone Hcl11$2,409
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$2,302
Duloxetine Hcl101$2,153
Buspirone Hcl101$1,709
Bupropion XlBupropion Hcl60$1,483
Trazodone Hcl89$1,313
Gabapentin88$1,106
Divalproex Sodium23$1,026
Doxepin Hcl49$991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$326$103,69646 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$94$38,74614 claims
Alkermes, Inc.Lybalvi$1,109$23,34115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Davie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →